MedTrace Logo

Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis

NCT01828294 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-04-03

No results posted yet for this study

Summary

The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients may or may not be receiving anticholinesterase agents. A common treatment for patients with this disease includes the administration of intravenous immunoglobulin (IVIG), which is a plasma protein that is given to help maintain adequate antibody levels to prevent infections and decrease the symptoms of the disease of Myasthenia Gravis. This study is being done to test if giving this medication in a subcutaneous form (into the fat of the abdomen, legs and thighs) will be better tolerated for patients with Myasthenia Gravis.

Conditions

Interventions

DRUG

Subcutaneous immunoglobulins

Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.

Sponsors & Collaborators

  • CSL Behring

    collaborator INDUSTRY

  • St. Louis University

    lead OTHER

Principal Investigators

  • Ghazala Hayat, M.D. · St. Louis University

  • Jafar Kafaie, M.D. · St. Louis University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01828294 on ClinicalTrials.gov